In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elan acquires Dura Pharmaceuticals for $1.69bn

Executive Summary

Elan has acquired Dura Pharmaceuticals (respiratory pharmaceuticals) in a tax-free, stock-for-stock transaction valued at $1.69bn. Dura shareholders will receive 0.6715 of an Elan ADS in exchange for one share, or $37.85, a (pr)38% premium based on the market average.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies